Form 4: Cytokinetics EVP Sells Shares Under 10b5-1 Plan

Cytokinetics' EVP, Chief Commercial Officer Andrew Callos, sold 1,809 shares of common stock for $62.44 per share under a Rule 10b5-1 plan.

Summary

• Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics Inc. (CYTK), reported a sale of common stock.
• The transaction involved the disposition of 1,809 shares of common stock.
• The shares were sold at a price of $62.44 per share.
• The transaction occurred on December 29, 2025.
• This sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Andrew Callos beneficially owns 51,353 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale under a 10b5-1 plan, which is generally considered neutral as it does not necessarily reflect a change in management's outlook on the company's prospects.

Future Outlook

NA

Industry Context

This is a routine insider transaction report (Form 4) and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A routine, pre-planned insider sale of this size is unlikely to have a significant impact on shareholder sentiment or the company's stock price.

Key Dates

Keywords

CYTOKINETICS, CYTK, Form 4, Insider Transaction, Stock Sale, Andrew Callos, EVP, Chief Commercial Officer, 10b5-1 Plan